The comparison changes when you keep the question attached
Four compound names can look like four answers to the same problem. I find the comparison much clearer when I keep what was measured beside each name.
Weight, deep fat and liver fat differ
Body weight, visceral fat and liver fat aren't interchangeable measurements. Visceral fat sits around abdominal organs; liver fat is inside the liver. A big percentage change in one can't simply be compared with a percentage change in another.
The people matter just as much. The semaglutide weight trial studied adults with overweight or obesity and without diabetes. The tesamorelin abdominal-fat trial studied adults with HIV and abdominal fat accumulation. Removing those details makes the comparison look simpler than it is.
| Compound | Main question | Limit to keep in view |
|---|---|---|
| AOD-9604 | Fat metabolism and weight loss | Human weight-loss benefit was not established |
| Retatrutide | Body weight and liver fat | Investigational; no FDA approval |
| Semaglutide | Weight and some heart and kidney outcomes | Results depend on the patient group and product |
| Tesamorelin | Deep abdominal fat in adults with HIV | Not approved for general weight loss |
Side by side isn't head to head
The retatrutide obesity trial and the semaglutide study weren't one shared experiment. Their participants weren't assigned between those two drugs. Different entry rules, lengths and study support can affect the results.
I can learn from both without declaring a winner. Nor can separate trials show that two drugs work better together. Different mechanisms can suggest a research question; they don't answer it.
What else would change the decision?
Side effects are part of the comparison. Semaglutide and retatrutide studies reported digestive problems, and the retatrutide trial recorded a heart-rate rise. Tesamorelin's label calls attention to blood sugar, IGF-1, a growth factor, and fluid retention. AOD-9604's human research leaves longer-term risks poorly understood.
That's why each name has its own page: AOD-9604, retatrutide, semaglutide and tesamorelin. A short table can orient you. It can't hold every warning or account for your medical history.
Access differs too. Retatrutide is investigational and cannot legally be compounded under federal law. Tesamorelin's approved products have a specific use. Compounded semaglutide is not FDA-approved. The word peptide doesn't settle any of those differences.
A useful comparison leaves you with better questions
I want to come away knowing what a proposed treatment is meant to change, and which study supports that aim. I also want to know what follow-up would involve and what could make the risks outweigh the benefit.
The AOD-9604 vs tesamorelin questions take the most easily confused pairing further. The reading list keeps the sources close by. You can use both to understand the conversation without turning this table into a treatment plan.